‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Data ReadoutpositivedaraxonrasibPositive

AI Analysis

Summary

Intellia Therapeutics reported significant demand for daraxonrasib through a compassionate use plan and identified the cause of liver toxicity, addressing a key safety concern. The positive early indicators have prompted analyst projections to be raised.

Outcome Details

Significant demand from compassionate use plan; safety question answered regarding liver toxicity

Importance:6/10

Sentiment:

0.70

compassionate_usesafety_dataliver_toxicitydemandgene_editing

Related Companies

$NTLA

Read the original article

Published by BioPharma Dive on August 7, 2026 2:02 PM

Read Original